The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2036, fueled by rising cancer incidence and the introduction of novel immunotherapies and targeted treatments. Key emerging therapies like Amivantamab, BNT113, and Petosemtamab are expected to transform treatment options and expand the market, which was valued at USD 850 million in 2025 across major markets including the US, EU4, UK, and Japan. Advances in immunotherapy, precision medicine, and combination treatments are improving outcomes for patients, while ongoing clinical trials and regulatory designations signal a dynamic and competitive landscape ahead.
In 2026, JPMorgan's Nasdaq-focused ETF (JEPQ) has delivered significantly higher monthly income distributions than its S&P 500-based sibling (JEPI), driven by the greater volatility and option premiums of the tech-heavy Nasdaq index. JEPI offers broa...
Jim Cramer recommended buying Johnson & Johnson (JNJ) shares during a recent dip, citing upcoming data from the Psych Congress conference and strong sales growth. Despite a 2.33% drop in the session, JNJ has outperformed the market with a 53.76% gain...
Johnson & Johnson announced new pivotal Phase 3 clinical data for CAPLYTA (lumateperone) in treating bipolar mania, alongside additional findings in bipolar depression and major depressive disorder. The data, presented at the 2026 Psych Congress, hig...
The JPMorgan Equity Premium Income ETF (JEPI) delivers attractive monthly income by selling call options, which caps its upside potential. In contrast, three Dividend Kings—Coca-Cola, Johnson & Johnson, and Procter & Gamble—offer lower initial yields...
In 2026, among defensive stocks, Johnson & Johnson outperformed with a 35% gain driven by strong oncology and immunology sales and a robust pipeline. Coca-Cola followed with a 28% rise, benefiting from steady global volume and pricing power, while Pr...
